Mural Oncology Welcomes New Talent with Inducement Grants
WALTHAM, Mass and DUBLIN – Mural Oncology plc (NASDAQ: MURA), a leading immuno-oncology company in the era of personalized medicine, has made significant strides in its mission to develop cutting-edge investigational therapies. In a recent announcement, the company disclosed that it has granted inducement stock options and restricted stock units to five newly hired employees, reinforcing its commitment to cultivating innovative talent within the organization.
Details of the Inducement Grants
On November 1, Mural Oncology issued non-statutory stock options totaling 23,500 ordinary shares and restricted stock units corresponding to 12,500 ordinary shares. These grants are part of the Company’s 2024 Inducement Stock Option and Incentive Plan, a strategic move aimed at attracting top-tier talent essential for advancing their promising pipeline of therapies.
Each stock option comes with an exercise price of $3.46 per share, aligning perfectly with the company’s closing share price on the grant date. The options boast a ten-year term and are designed to vest over four years. Specifically, 25% of the granted shares will vest on the first anniversary of the grant, with 6.25% vesting quarterly thereafter, contingent on the employees' continued service with Mural Oncology.
Understanding the Vesting Schedule
In tandem with the stock options, the restricted stock units will also vest over a four-year period. This structure ensures that a quarter of the units vest annually on the anniversary of the grant date. Like the stock options, the vesting is subject to the employees remaining with Mural Oncology, showcasing the company’s dedication to long-term talent retention.
About Mural Oncology
Mural Oncology stands out in the biotechnology landscape by leveraging a unique protein engineering platform to create novel cytokine-based immunotherapies. These innovative approaches are designed to address the pressing needs of cancer patients, focusing on enhancing their quality of life and clinical outcomes. The company emphasizes bridging the gap in therapeutic options for diverse cancer types, with a lead candidate named nemvaleukin currently undergoing potentially registrational trials for treating mucosal melanoma and platinum-resistant ovarian cancer.
With its headquarters in Dublin, Ireland, and primary research facilities in Waltham, Mass, Mural Oncology is poised for growth and breakthroughs in the evolving world of cancer therapies. Their mission emphasizes a commitment to improving patient outcomes through science-driven innovation.
Connecting with Mural Oncology
For those interested in learning more about Mural Oncology’s initiatives, therapies, and ongoing trials, a wealth of information is available on their website. The company invites visitors to explore the transformative nature of their research and forward-thinking vision in cancer treatment.
Contact Information
For media inquiries or additional information regarding the company’s latest developments, you can reach out to Katie Sullivan at Mural Oncology. She is available to answer questions and provide insights regarding the company’s strategic initiatives.
Katie Sullivan
katie.sullivan@muraloncology.com
Frequently Asked Questions
What new grants has Mural Oncology announced?
Mural Oncology announced inducement grants for five new employees, including stock options and restricted stock units as part of their incentive plan.
What is the purpose of these inducement grants?
These grants aim to attract and retain top talent crucial for advancing the company's innovative cancer therapies.
What are the terms for the stock options granted?
The stock options have a ten-year term, with a 25% vesting on the first anniversary, followed by quarterly vesting.
What is Mural Oncology's lead drug candidate?
Nemvaleukin is the lead candidate currently in potentially registrational trials for treating mucosal melanoma and ovarian cancer.
How can I contact Mural Oncology for more information?
For inquiries, you can contact Katie Sullivan via email at katie.sullivan@muraloncology.com.
